129 related articles for article (PubMed ID: 24382070)
1. Edoxaban versus warfarin for venous thromboembolism.
Haft JI
N Engl J Med; 2014 Jan; 370(1):80. PubMed ID: 24382070
[No Abstract] [Full Text] [Related]
2. Edoxaban versus warfarin for venous thromboembolism.
Büller HR
N Engl J Med; 2014 Jan; 370(1):80-1. PubMed ID: 24382069
[No Abstract] [Full Text] [Related]
3. ACP Journal Club. Edoxaban was noninferior to warfarin for preventing recurrent venous thromboembolism, with less bleeding.
Thomé S
Ann Intern Med; 2014 Jan; 160(2):JC4. PubMed ID: 24445714
[No Abstract] [Full Text] [Related]
4. Venous thromboembolism: Edoxaban: as effective and safer than warfarin in VTE.
Lim GB
Nat Rev Cardiol; 2013 Nov; 10(11):614. PubMed ID: 24042227
[No Abstract] [Full Text] [Related]
5. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
; Büller HR; Décousus H; Grosso MA; Mercuri M; Middeldorp S; Prins MH; Raskob GE; Schellong SM; Schwocho L; Segers A; Shi M; Verhamme P; Wells P
N Engl J Med; 2013 Oct; 369(15):1406-15. PubMed ID: 23991658
[TBL] [Abstract][Full Text] [Related]
6. Which oral anticoagulant to use: factor Xa inhibitor or thrombin inhibitor?
DAS S
Natl Med J India; 2013; 26(4):221-2. PubMed ID: 24758448
[No Abstract] [Full Text] [Related]
7. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
8. In intracranial artery stenosis, adding angioplasty and stenting to medical therapy increased stroke or death.
Hankey GJ
Ann Intern Med; 2014 Mar; 160(6):JC4. PubMed ID: 24638182
[No Abstract] [Full Text] [Related]
9. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
11. [Current status of the management of venous thromboembolism in Japan].
Nakamura M
Nihon Rinsho; 2014 Jul; 72(7):1298-302. PubMed ID: 25163325
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
[TBL] [Abstract][Full Text] [Related]
13. Venous Thromboembolism Prophylaxis: Safe, but Still Provocative?
Pelargos PE; Dunn IF
Thromb Haemost; 2019 Nov; 119(11):1716-1718. PubMed ID: 31665802
[No Abstract] [Full Text] [Related]
14. Optimal duration of anticoagulation after venous thromboembolism.
Goldhaber SZ; Piazza G
Circulation; 2011 Feb; 123(6):664-7. PubMed ID: 21321182
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
Preblick R; Kwong WJ; White RH; Goldhaber SZ
Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
[TBL] [Abstract][Full Text] [Related]
16. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
Sprynger M
Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
[TBL] [Abstract][Full Text] [Related]
17. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
18. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
19. Tinzaparin vs Warfarin for Acute Venous Thromboembolism.
Maruyama A; Tejani AM; Perry TL
JAMA; 2016 Jan; 315(2):200. PubMed ID: 26757471
[No Abstract] [Full Text] [Related]
20. Tinzaparin vs Warfarin for Acute Venous Thromboembolism--Reply.
Khorana AA; Lee AY;
JAMA; 2016 Jan; 315(2):200-1. PubMed ID: 26757472
[No Abstract] [Full Text] [Related]
[Next] [New Search]
